anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Early diagnosis of relative afferent pupillary defects (RAPDs) in patients with ocular trauma is crucial for timely management and improved outcomes. However, clinical examination can be challenging for patients with periorbital ecchymosis. This study aimed to compare the diagnostic accuracy of point-of-care ultrasound (POCUS) and clinical examination by emergency physicians for detecting RAPD in adult ocular trauma patients and to evaluate the proportion of RAPD in patients with ocular trauma who presented to the ED.
METHODS: This prospective cohort study was conducted at an academic emergency department in South India. Adult ocular trauma patients were assessed for RAPD using clinical examinations by emergency physicians and POCUS. The diagnostic accuracies of both methods were compared, with the ophthalmologist's final diagnosis serving as the gold standard. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for both techniques.
RESULTS: A total of 376 patients (median age, 35 years) were included in this study. RAPD was identified in 14.63% of the patients. The sensitivity and specificity of POCUS in detecting RAPD were 92.73% and 99.38%, respectively, which were higher than those of clinical examination, with a sensitivity of 81.82% and specificity of 99.07%. The PPV and NPV of the clinical examination were 93.75% and 96.95%, respectively, whereas the PPV and NPV of POCUS were 96.23% and 98.76%, respectively. POCUS accurately diagnosed RAPD in patients with periorbital ecchymosis.
CONCLUSION: POCUS-guided RAPD assessment proves to be a better diagnostic adjunct compared to clinical examination in patients with ocular trauma presenting to the emergency department.
Various embodiments for customizing electronic medical records system are described herein. An embodiment operates by receiving a request from a doctor to generate a medical diagnosis for a patient. One or more preconfigured templates corresponding to the medical diagnosis input by the doctor are identified. A selection of at least one of the identified one or more preconfigured templates is received. Text of the selected at least one of the identified one or more preconfigured templates is copied into a treatment plan for the patient. The treatment plan including at least a portion of the copied text of the selected at least one of the identified one or more preconfigured templates is provided to the patient.
The present invention relates to a Lugua polypeptide for injection and a preparation method thereof. Lugua extract has main components of peptide substances, and various kinds of alkaloid and tannin contained in white melon seeds, peptide substances are easily polymerized into macromolecules, and the alkaloid and tannin in the white melon seeds can accelerate the polyreaction. Therefore, liquid Lugua polypeptide extract is easily polymerized in the process of storage to cause the increase of clinic anaphylactic reactions. The Lugua polypeptide for injection is prepared from 5 to 100 parts by weight of polypeptide substance and 20 to 90 parts by weight of excipient, wherein the polypeptide substances are extracted from cervidae animal bones and cucurbitaceous muskmelon seeds, the molecular weight of the polypeptide substances is from 3000 to 10000 D, and the pH value of the polypeptide substances is from 3.5 to 9.0; polypeptide substances form a solution representing purplish red after reacting with biuret, are off-white blocks or amorphous powder, and are easily soluble in water. The Lugua polypeptide for injection treats rheumatism, rheumatoid arthritis, hypertrophic arthritis, waist pain. Leg pain, fractures, wounds, etc.
This study is a single arm phase II study treating patients with newly diagnosed double-hit MM with DVRd induction therapy. This study will enroll 40 patients with double-hit MM who are eligible for autologous stem cell transplantation (ASCT) to evaluate the efficacy of DVRd and the feasibility of MRD guided maintenance therapy. The protocol is: DVRd induction therapy for 4 cycles, followed by ASCT, then DVRd consolidation therapy for 4 cycles, and the last DVR maintenance therapy. After induction therapy, during 60 to 90 days after ASCT, after consolidation therapy, and every 4 cycles during maintenance therapy, the patients will accept MRD monitoring. Patients with MRD negative for at least 12 months will enter the maintenance phase of lenalidomide monotherapy. Otherwise, they will accept DVR maintenance therapy for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
PURPOSE: To provide a medicinal compsn. for oral medication contg. bupropion hydrochloride as effective components enabling the continuous release of effective components by a controlled method. CONSTITUTION: This medicinal compsn. for oral medication is obtd. by pharmaceutical preparing the bupropion hydrochloride as the effective components together with a solid medicinal carrier to continuously release the effective components by the controlled method. At least 10%, more preferably 10 to 45% of the effective components of the compsn. are released for 2 hours, at least 25%, more preferably 25% to 70% for 4 hours, and at least 40%, more preferably 40 to 90% for 6 hours. The compsn. consists of the compd. contg. the water-soluble effective components, a semipermeable membrane enveloping the compd. and granular water-soluble pore forming substances dispersed into this membrane.  The pore forming substances are dissolved in an aq. environment to form the pores in the semipermeable membrane, by which the effective components are dissolved in the soln. and the osmotic pressure gradient crossing the membrane is generated. As a result, the soln. of the effective components is discharged into the water environment.
Young adults (18-35 years) with mixed anxiety/depression. Intervention as for all groups but with added focus on "acceptance and commitment therapy", behavioral analysis, metacognitive therapy and physical activity.
The invention relates to a preparation method of a traditional Chinese medicine for treating skin dryness. The method comprises the following steps: extracting 5g to 12g of mulberry leaves baked with honey, 10g to 12g of burdock, 6g to 9g of fermented soya beans, 6g to 9g of burdock, 10g to 16g of bulbus fritillariae cirrhosae, 3g to 7g of fructus gardeniae, 5g to 18g of licorice root, 5g to 8g of vaseline and 8g to 11g of radix glehniae twice by adding water, wherein for the first time, soaking for 0.5 hour and decocting for 2 hours by adding the water which is five times as the adding amount of the traditional Chinese medicines; for the second time, decocting for 1 hour by adding the water which is ten times as the adding amount of the traditional Chinese medicine; then mixing medicine liquids obtained twice; heating and concentrating the mixed medicine liquid to reach 500ml; and adding 5g to 8g of vaseline into the mixed medicine liquid. Thus, the medicine liquid can be used for smearing skin, and has the functions of anti-inflammation and lubrication. The method is simple and few in steps. The traditional Chinese medicine is rapid in efficacy, good in effect, capable of relieving the pain of a patient, simple in formula and low in cost. The traditional Chinese medicine can be used for complementing lung qi so as to increase body health.
A semi-solid, fast-breaking cleansing emulsion comprises (a) 20-70% by weight of water, (b) a non-polar organic solvent, preferably 30-75% by weight of the composition of kerosene or a blend of kerosene with a petroleum fraction having a boiling range between that of kerosene and petrol such as naphtha, and (c) an organic ammonium clay complex.  The composition preferably includes less than 10% by weight of a detergent or emulsifying agent, particularly ethylene oxide condensates with fatty acids and amines, or with alkylphenols; triethanolamine alkyl sulphate is also suitable.  The composition may also contain up to 10% (1-20% of the oil phase) of a polar organic liquid, for example aliphatic alcohols containing less than 4 carbon atoms, especially isopropanol, or lower ketones.  The only clay complex (c) referred to is dimethyl dioctadecyl ammonium bentonite.  Lanolin, polyvinyl pyrrolidone, citric acid, white oil, diethylene glycol and perfume may also be incorporated.  When only the three essential ingredients are present the mixture is made up by adding the clay complex to the solvent at an elevated temperature, usually about 65 DEG C. with agitation, and finally adding the water. If an emulsifier is also present, it is mixed with the non-polar solvent with application of heat, and the mixture rapidly agitated while the clay complex and then subsequently the water is added. If the polar liquid is also to be incorporated the mixture is made up in a similar manner, the polar and non-polar solvents being first mixed separately.  In all cases, the final mixture is passed through a colloid mill or homogluizer.  U.S.A. Specification 2,531,427 is referred to.
The present invention relates to the treatment of mast cell activation diseases (MCAD). The present invention is based on the discovery that aminoquinoline compound (such) can improve clinical symptoms present in several MCAD patients. In all patients, six months after HCQ treatment initiation, a significant improvement of MC activation symptoms was observed. These clinical observations prompted to investigate the biological effects of hydroxychloroquine (HCQ) treatment on human mast cells (MCs) in vitro. The results indicate that HCQ treatment modifies key features of MC biology and induces a profound alteration of MC granules homeostasis (storage of inactive tryptase and decreased expression of key MC inflammatory mediator). Taken together, the HCQ induced dramatic reduction of MC inflammatory capabilities contributing to the observed efficacy of HCQ in MCAD patients. Accordingly, the present invention relates to an aminoquinoline compound (such HCQ) for use in the treatment of MACD such as mastocytosis and mast cell activation syndromes (MCAS).
OBJECTIVES: Childhood obesity is a growing global problem that can be prevented by improving diet quality. Mediterranean diet (MedDiet), historically present in Mediterranean countries, is considered one of the healthiest dietary patterns. This cross-sectional study aimed to determine the MedDiet adherence and anthropometric parameters in 9-year-old children from the central geographic locations of Split-Dalmatia County, Croatia.
METHODS: The study analysed data obtained from 158 children aged nine years from central parts of Dalmatia: Split and Hvar. To assess the MedDiet adherence, the parents of the children filled out the Mediterranean Diet Index (KIDMED) questionnaire. Appointed school medicine specialists collected anthropometric data of the children and categorized them into body mass index (BMI) categories according to the Center for Disease Control and Prevention (CDC) criteria. Additionally, we assessed the influence of parents' education degree on children's MedDiet adherence and anthropometric measures.
RESULTS: Results showed that more than a quarter of nine-year-olds included in this study were overweight or obese (BMI ≥ 85th percentile for age and sex). One of the main findings was that 72% of children had suboptimal (poor or average) MedDiet adherence. Moreover, children with suboptimal KIDMED results (KI < 8) had significantly higher body weight, waist circumference, hip circumference, and waist-to-height ratio. Also, results showed that mothers' education notably influences children's anthropometry.
CONCLUSION: Our study found that childhood obesity is a significant concern among 9-year-olds, with a high prevalence of overweight and obesity. Additionally, our results showed that MedDiet adherence is suboptimal among this age group. These results indicate that children of the Mediterranean are not spared of modern life challenges. This problem should be prioritized in the future to prevent the development of a metabolically compromised adult population.
Obesity is the best described risk factor for the development of non-alcoholic fatty liver disease (NAFLD)/metabolic dysfunction associated steatotic liver disease (MASLD) and polycystic ovary syndrome (PCOS) while the major pathogenic mechanism linking these entities is insulin resistance (IR). IR is primarily caused by increased secretion of proinflammatory cytokines, adipokines, and lipids from visceral adipose tissue. Increased fatty acid mobilization results in ectopic fat deposition in the liver which causes endoplasmic reticulum stress, mitochondrial dysfunction, and oxidative stress resulting in increased cytokine production and subsequent inflammation. Similarly, IR with hyperinsulinemia cause hyperandrogenism, the hallmark of PCOS, and inflammation in the ovaries. Proinflammatory cytokines from both liver and ovaries aggravate IR thus providing a complex interaction between adipose tissue, liver, and ovaries in inducing metabolic abnormalities in obese subjects. Although many pathogenic mechanisms of IR, NAFLD/MASLD, and PCOS are known, there is still no effective therapy for these entities suggesting the need for further evaluation of their pathogenesis. Extracellular vesicles (EVs) represent a novel cross-talk mechanism between organs and include membrane-bound vesicles containing proteins, lipids, and nucleic acids that may change the phenotype and function of target cells. Adipose tissue releases EVs that promote IR, the development of all stages of NAFLD/MASLD and PCOS, while mesenchymal stem cell-derived AVs may alleviate metabolic abnormalities and may represent a novel therapeutic device in NAFLD/MASLD, and PCOS. The purpose of this review is to summarize the current knowledge on the role of adipose tissue-derived EVs in the pathogenesis of IR, NAFLD/MASLD, and PCOS.
Shake well before every administration. To administer ZONISADE directly into the mouth, it is important that ZONISADE be measured with an accurate measuring device [see Overdosage (10)]. A household teaspoon is not an accurate measuring device. A pharmacist will provide an appropriate device and instructions for measuring the correct dose.

Administer ZONISADE orally with or without food.

Discard unused portion of ZONISADE 30 days after first opening the bottle.
BACKGROUND: Progressive supranuclear palsy (PSP) is a rare neurodegenerative brain disease with rapid progression and currently limited treatment options. A comprehensive understanding of disease progression, management, and healthcare resource utilization is limited, and further research is challenging due to the small population of patients. To address these challenges in conducting PSP research, individuals with PSP were recruited using a multichannel approach tailored specifically to the PSP community. We performed a retrospective observational study using data abstracted from participant medical records collected from multiple patient care centers.
RESULTS: Seventy-two individuals with PSP were eligible for inclusion. On average, 144 medical documents per participant were collected from an average of 2.9 healthcare centers per participant, with a mean study period of 7.9 years. Among participants with a date of symptom onset documented in the medical records, the median time for the onset of the first fall was 2.0 years (IQR 3.2) before diagnosis, the median onset of unsteady gait or gait impairment was 1.2 years (IQR 1.8) before diagnosis, and the median onset of mobility problems was 0.8 years (IQR 1.8) before diagnosis. The most widely utilized healthcare resources, with at least 85% of participants using each of these resources at some point during the disease course, were medications (100%), imaging (99%), assistive devices (90%), supportive care (86%), and surgeries and procedures (85%).
CONCLUSIONS: This retrospective study adds to the current understanding of PSP symptoms, comorbidities, and healthcare resource utilization (HRU) across the disease journey. By involving individuals with PSP and their caregivers or legally authorized representatives in the research process, this study was unique in its approach to participant recruitment and enabled individuals to participate in research without the need for travel. We collected medical documents from multiple healthcare centers, allowing for broad data collection covering the entire disease journey. This approach to the collection of real-world data may be used to generate valuable insights into many aspects of disease progression and management in PSP and many other rare diseases.
To treat anxiety, conventional medicine relies on medicines such as benzodiazepines, antidepressants, barbiturates, and antihistamines. However, several authors have reported western medicine cannot resolve all anxiety diseases and the risk of side effects, resistance to pharmacological treatments affects approximately one in three patients with anxiety disorders.

Alternatively, auriculotherapy is a technique similar to reflexology. It is speculated the technique might work in anxiety because groups of pluripotent cells contain information from the whole organism creating regional organization centres representing different parts of the body, through the recruitment of more cortex cells dedicated to specific body areas. Thus reflex points in the ear can incite body responses by the stimulation of reticular formation and the sympathetic and parasympathetic nervous systems. The information that comes from the thermal, Algic and proprioceptive stimuli are transmitted from the auricular pavilion by the fibres of the nerves: trigeminal; Auricular magnum and minor occipital (sensitive branch of the cervical plexus) and the vagus nerve. The vagus nerve is responsible for the parasympathetic innervation of the lung, heart, stomach, and small intestine, as well as the pharynx and larynx muscles and it also sends information to important brain regions (e.g., locus coeruleus, orbitofrontal cortex, hippocampus and at amygdala) in the regulation of anxiety. In turn, the trigeminal nerve controls, mainly, the mastication muscles and the facial sensitivity while the cervical plexus nerve is responsible for neck muscles, diaphragm, and thorax.
Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
Parents assigned to the intervention arm will receive a lipid-rich emollient and educational materials promoting once daily full-body emollient use until their infant is 24 months old. Parents will select one of five emollients to be mailed to the dyad's home at enrollment and approximately every six months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2) Vaseline, (3) Cetaphil cream, (4) CeraVe cream, and (5) Vanicream.
A vaginal fistula is a devastating condition, affecting an estimated 2 million girls and women across Africa and Asia. Finding ways of providing services in a more efficient and cost-effective manner, without compromising surgical outcomes and the overall health of the patient, is paramount. Shortening the duration of urethral catheterization following fistula repair surgery would increase treatment capacity (by freeing available bed space and increasing availability of nursing staff), lower costs of services, and potentially lower risk of healthcare-associated infections among fistula patients. There is a lack of empirical evidence supporting any particular length of time for urethral catheterization following fistula repair surgery.

This facility-based, multi-center randomized controlled trial (RCT) will test the non-inferiority of short-term (7 day) urethral catheterization compared to longer-term (14 day) urethral catheterization in terms of predicting fistula repair breakdown. The primary outcome is fistula repair breakdown three months following fistula repair surgery as assessed by a urinary dye test, a routine practice in fistula repair services. t. Secondary outcomes will include repair breakdown one week following catheter removal, intermittent catheterization due to urinary retention and the occurrence of septic or febrile episodes, prolonged hospitalization (defined as a stay at the facility beyond one week following initial catheter removal related to an adverse event), catheter blockage, and self-reported residual incontinence. This study will be conducted among 507 women with simple fistula presenting at 8 study sites for fistula repair surgery over the course of 16-18 months at each site.
Lysine lactylation is a post-translational modification that links cellular metabolism to protein function. Here, we find that AARS1 functions as a lactate sensor that mediates global lysine lacylation in tumor cells. AARS1 binds to lactate and catalyzes the formation of lactate-AMP, followed by transfer of lactate to the lysince acceptor residue. Proteomics studies reveal a large number of AARS1 targets, including p53 where lysine 120 and lysine 139 in the DNA binding domain are lactylated. Generation and utilization of p53 variants carrying constitutively lactylated lysine residues revealed that AARS1 lactylation of p53 hinders its liquid-liquid phase separation, DNA binding, and transcriptional activation. AARS1 expression and p53 lacylation correlate with poor prognosis among cancer patients carrying wild type p53. β-alanine disrupts lactate binding to AARS1, reduces p53 lacylation, and mitigates tumorigenesis in animal models. We propose that AARS1 contributes to tumorigenesis by coupling tumor cell metabolism to proteome alteration.
Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
NEW MATERIAL:A propenedicarboxylic acid derivative expressed by formula  I (A is decanyl or decenyl; B is formula II or III), anhydride or salt thereof. EXAMPLE:1-(9-Decenyl)-1-propene-1,3-dicarboxylic acid. USE:An inhibitor for biosynthesis of fatty acids. PREPARATION:A microorganism, belonging to the genus Gongronella, and having the ability to produce the compound expressed by formula I , e.g. Gongronella butleri M3180 (FERM-P No.6975), is cultivated to produce and accumulate the compound depressed by formula I in the culture fluid. The resultant compound is collected to afford the aimed compound expressed by formula I .